Sugi Predict

Sugi Predict / Compounds / SCHEMBL6026003

SCHEMBL6026003

SCHEMBL6026003

CC(=O)N[C@H](CCCNC(=N)N)C(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FOLH1 Q04609 2/20 0.49
▸ GNPAT O15228 2/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.47
▸ KDM4E B2RXH2 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ THRB P10828 1/20 0.44
▸ ALOX15 P16050 1/20 0.44
▸ NFKB1 P19838 1/20 0.44
▸ PTGS2 P35354 1/20 0.44
▸ THPO P40225 1/20 0.44
▸ RECQL P46063 1/20 0.44
▸ BLM P54132 1/20 0.44
▸ ALB P02768 3/20 0.44
▸ SIRT6 Q8N6T7 1/20 0.43
▸ SIRT1 Q96EB6 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ SIRT5 Q9NXA8 3/20 0.42
▸ C3AR1 Q16581 1/20 0.40
▸ NOD1 Q9Y239 2/20 0.39
▸ CHRM2 P08172 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30526285 1.00 FOLH1 (0.49) FOLH1GNPATSMN1; SMN2KDM4EMAPT
SCHEMBL468901 1.00 FOLH1 (0.49) FOLH1GNPATSMN1; SMN2KDM4EMAPT
SCHEMBL446929 1.00 FOLH1 (0.49) FOLH1GNPATSMN1; SMN2KDM4EMAPT
Acetic Acid SCHEMBL28406175 0.98 FOLH1 (0.48) FOLH1GNPATSMN1; SMN2KDM4EMAPT
SCHEMBL9438405 0.98 FOLH1 (0.48) FOLH1GNPATSMN1; SMN2KDM4EMAPT
Water SCHEMBL29401510 0.98 FOLH1 (0.48) FOLH1GNPATSMN1; SMN2KDM4EMAPT
Hydrochloric Acid SCHEMBL4422480 0.98 FOLH1 (0.48) FOLH1GNPATSMN1; SMN2KDM4EMAPT
SCHEMBL468736 0.95 FOLH1 (0.55) FOLH1GNPATSMN1; SMN2KDM4EMAPT
SCHEMBL22769501 0.95 FOLH1 (0.55) FOLH1GNPATSMN1; SMN2KDM4EMAPT
SCHEMBL29550463 0.95 FOLH1 (0.55) FOLH1GNPATSMN1; SMN2KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120152725-A Methods of treating obesity using MC4R agonists 节奏制药公司 2025-06-13 — — CN claimed
CN-105837661-B Melanocortin receptor ligands 益普生制药股份有限公司 2024-10-15 — — CN claimed
EP-4100040-A1 DIAMINE-LINKED RECEPTOR-SPECIFIC CYCLIC PEPTIDES Palatin Technologies, Inc. (US) 2022-12-14 — — EP claimed
CN-1874992-A Resolution of 3-amino alkylnitriles PFIZER (US) 2006-12-06 — — CN claimed
EP-1689703-A1 RESOLUTION OF 3-AMINO ALKYLNITRILES Pfizer Products Inc. (US) 2006-08-16 — — EP claimed
US-7026345-B2 Resolution of 3-amino alkylnitriles PFIZER INC. (US) 2006-04-11 — — US claimed
US-20050107453-A1 Resolution of 3-amino alkylnitriles PFIZER INC. 2005-05-19 — — US claimed
WO-2005040097-A1 RESOLUTION OF 3-AMINO ALKYLNITRILES PFIZER PRODUCTS INC. (US) 2005-05-06 — — WO claimed
US-12616761-B2 CXCR4-targeting compounds THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2026-05-05 — — US disclosed
US-20260085092-A1 MELANOCORTIN RECEPTOR LIGANDS IPSEN PHARMA SAS (FR) 2026-03-26 — — US disclosed
CN-120718096-A Liquid phase synthesis method of eptic peptides 深圳翰宇药业股份有限公司 2025-09-30 — — CN disclosed
US-20250276116-A1 METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION TUFTS MEDICAL CENTER, INC. 2025-09-04 — — US disclosed
US-20250242064-A1 CXCR4-TARGETING COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME ALPHA-9 ONCOLOGY INC. (CA) 2025-07-31 — — US disclosed
CN-120152725-A Methods of treating obesity using MC4R agonists 节奏制药公司 2025-06-13 — — CN disclosed
US-7026345-B2 Resolution of 3-amino alkylnitriles PFIZER INC. (US) 2006-04-11 — — US disclosed
US-20050107453-A1 Resolution of 3-amino alkylnitriles PFIZER INC. 2005-05-19 — — US disclosed
WO-2005040097-A1 RESOLUTION OF 3-AMINO ALKYLNITRILES PFIZER PRODUCTS INC. (US) 2005-05-06 — — WO disclosed
EP-0673432-B1 PROCESS FOR PREPARING CLAVULANIC ACID SMITHKLINE BEECHAM PLC (GB) 1999-03-24 — — EP disclosed
US-5869299-A USING AN ENZYME SYSTEM FROM STREPTOMYCES, PARTICULARLY S. CLAVULIGERUS. SMITHKLINE BEECHAM P.L.C. (GB) 1999-02-09 — — US disclosed
WO-1994012654-A1 PROCESS FOR PREPARING CLAVULANIC ACID SMITHKLINE BEECHAM PLC (GB) 1994-06-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250242064-A1 CXCR4-TARGETING COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME CXCR4, CXCL12, ACKR3 FOLH1 497/4885GNPAT 1195/4885SMN1; SMN2 3537/4885
US-20050107453-A1 Resolution of 3-amino alkylnitriles AADAT, AANAT, AAAS FOLH1 3707/4885GNPAT 316/4885SMN1; SMN2 3759/4885
US-12616761-B2 CXCR4-targeting compounds CXCR4, CXCR2, CXCR3 FOLH1 756/4885GNPAT 1494/4885SMN1; SMN2 4042/4885
US-20260085092-A1 MELANOCORTIN RECEPTOR LIGANDS THRB, MC1R, MC5R FOLH1 1212/4885GNPAT 1000/4885SMN1; SMN2 4773/4885
US-20250276116-A1 METHODS OF MITIGATING MYOCARDIAL DAMAGE DUE TO EXTRACORPOREAL MEMBRANE OXYGENATION TNNI3, TNNT2, MB FOLH1 2095/4885GNPAT 3291/4885SMN1; SMN2 2149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.